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Abstract
Breast cancer arising at a young age is relatively
uncommon, particularly in the developed world. Several
studies have demonstrated that younger patients often
experience a more aggressive disease course and have
poorer outcome compared to older women. Expression
of key biomarkers, including endocrine receptors, HER2
and proliferation markers, appears to be different in
younger patients and young women are more likely to
harbor a genetic predisposition. Despite these
differences, little research to date has focused on the
biology of these tumors to refine prognosis, and
potentially direct treatment strategies, which remain
similar to those offered to older patients. Accumulating
evidence suggests the differences in breast stroma in
younger patients and changes that occur with
pregnancy and breastfeeding likely contribute to the
different biology of these tumors. Reproductive
behaviors appear to impact the biology of tumors
developing later in life. In addition, tumors arising during
or shortly following pregnancy appear to exhibit unique
biological features. In this review, we discuss our
emerging understanding of the biology of breast cancer
arising at a young age at both the pathologic and the
genomic level. We elucidate the potential role of
genomic signatures, the impact of pregnancy and
breastfeeding on breast cancer biology, and how even
current knowledge might advance the clinical
management of young breast cancer patients.
Introduction
Breast cancer is predominantly a disease of aging, with only
5 to 7% of patients diagnosed below the age of 40 years in
the developed world [1]. In less developed regions where
population-based screening is not routine and populations
are much younger on average, such as in Africa and the
Middle East, a higher proportion of patients are diagnosed
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below the age of 40, reaching as high as 20% [2,3].
Whether there are underlying genetic differences or envir-
onmental factors that would render women in Africa and
the Middle East more prone to develop the disease at
a young age is the subject of ongoing research [4].
Nevertheless, young age at diagnosis of breast cancer
has emerged world-wide as an independent factor associ-
ated with higher risk of relapse and death in several large
studies, even when more aggressive therapies are adminis-
tered [5-9] (Table 1). Expression of key biomarkers, includ-
ing endocrine receptors, HER2 and proliferation markers,
appears to be different in younger patients. Recent studies
have attempted to control for tumor molecular subtypes,
recognizing that more aggressive subtypes are more com-
mon in younger women. Two studies suggested particu-
larly worse outcomes in young patients compared to older
women with luminal-B tumors [7,9]. It was hypothesized
that younger patients were not offered standard hormonal
therapy until a decade ago, and compliance to hormonal
therapy is lower in young patients [10]. However, a study
of women who were untreated with systemic adjuvant
therapy also demonstrated poorer outcomes of young
luminal-B patients [9]. These collective findings suggest
that tumors arising in younger patients may be more ag-
gressive due to biological differences. In this review we dis-
cuss the biological features of breast cancer arising in
young women, and the emerging relationship with repro-
ductive behaviors, including pregnancy and breastfeeding,
and their potential clinical implications.
Pathological features of tumors arising in young
women
Recently, results of the largest prospective observation
study evaluating the pathological features and outcome
of women who were aged <40 years at diagnosis were re-
ported [11]. This UK-based study included 2,956 pa-
tients diagnosed with breast cancer between 2000 and
2008. The median age at diagnosis was 36 years, and the
majority had ductal histology (86.5%), and grade III
(58.9%) tumors. Node-positive disease and multifocality
were observed in 50.2% and 27%, respectively. One third
of tumors were estrogen receptor (ER)-negative while
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observed among the first 399 patients evaluated in the
Young Women’s Breast Cancer Study, which started in
2006 enrolling women aged 40 years or younger at diag-
nosis [12]. This study further demonstrated high rates of
lymphovascular invasion and lymphocytic infiltration, in
34% and 24% of patients, respectively.
Several other retrospective studies have evaluated differ-
ences in pathological features according to age [5,13-15].
Gnerlich and colleagues [5] conducted the largest ana-
lysis including more than 200,000 patients of whom nearly
15,000 were aged <40 years at breast cancer diagnosis
from a Surveillance, Epidemiology, and End Results data-
base. Young patients were more commonly diagnosed with
larger tumors (P< 0.0001), nodal involvement (P< 0.0001),
poorly differentiated tumors (P< 0.0001), and endocrine
receptor-negative tumors (P< 0.0001). A population-based
study from the California Cancer Registry, which included
5,605 patients aged <40 years at diagnosis, further showed
higher expression of HER2 in the younger population
[15]. Several other hospital-based studies confirmed the
same findings [13,14], underscoring that tumors diag-
nosed in younger patients have more aggressive patho-
logical features.
Pattern of breast cancer subtypes according to age
In recent years, breast cancer has been increasingly
recognized as a heterogeneous disease with at least four
subtypes: luminal-A, luminal-B, basal-like and HER2-
enriched subtypes [16]. Figure 1 summarizes the two
studies that have addressed the pattern of breast cancer
molecular subtypes according to age using gene expression
profiling. In the largest published study to date, Azim and
colleagues [9] evaluated tumors of 3,522 patients, of whom
451 were aged ≤40 years at the time of breast cancer diag-
nosis. Young patients had a significantly higher proportion
of basal-like tumors (34.3%) compared to 27.7%, 20.8% and
17.9% in patients aged 41 to 52, 53 to 64 and ≥65 years,
respectively (P<0.0001). A higher proportion of HER2-
enriched tumors was also observed in young patients. On
the other hand, young women were less likely to have
luminal-A tumors (17.2%) compared to 30.7%, 35.1% and
35.4% in the other age groups (P< 0.0001).
Other studies have addressed the question using im-
munohistochemical surrogates with variable definitions
[7,12,17,18] (Figure 2). This has resulted in different dis-
tributions of subtypes observed in the different studies.
Of note, these studies were also hospital-based with po-
tential for selection bias. The California Cancer Registry
examined the differences in breast cancer subtypes accor-
ding to age (<40, 40 to 49 and ≥50 years) but only based
on the expression of ER and HER2 [15]. In line with other
studies, there was a lower prevalence of ER-positive/
HER2-negative tumors in younger patients (49% versus
63.9% versus 71.6%), but a high proportion of triple-nega-
tive tumors (22.8% versus 14.3% versus 11.7%), and also
HER2 expression irrespective of ER status.
Differences in pathological features and subtypes
within premenopausal patients: does actual
age matter?
In the previously discussed studies, different age cutoffs
were used to define 'young age'. In addition, the term
'young age' has often been used synonymously with 'pre-
menopausal' in evaluations of women with breast cancer,
requiring further evaluation of whether differences exist
within the premenopausal population according to actual
age. In 2002, Colleoni and colleagues [13] published a large
analysis including 1,427 premenopausal patients who were
aged ≤50 years at the time of breast cancer diagnosis. They
compared the expression of ER, progesterone receptor
(PgR), and ki67 and other features by young age group
(<35, 35 to 40, 40 to 45 and 45 to 50 years). Significant dif-
ferences were observed according to age, with aggressive
Table 1 Recent large studies investigating the impact of age on breast cancer prognosis
Young age,
years (n)
Control age,
years (n)
Outcome
definition
Impact of young age on outcome
a Factors controlled in
multivariate model Hazard ratio 95% CI
Gnerlich et al. 2009 [5] <40 (15,548) ≥40 (227,464) BC-specific survival 1.39 1.34-1.45 T, N, grade, race, marital
status, ER, PgR, local therapy
Fredholm et al. 2009 [6] <35 (378) 50-69 (13,486) BC-specific survival 1.76 1.36-2.28 T, N, grade, ER, multifocality,
local and systemic therapy
Cancello et al. 2010 [7] <35 (315) 35-50 (2,650) BC-related event 1.7 1.33-2.18 T, N, grade, histology, ER, HER2,
PgR, ki67 vascular invasion
Han et al. 2010 [8] <35 (1,443) 40-50 (6,354) Overall survival 30-34 years: 1.43
26–29 years: 1.97
1.18-1.74 1.48-2.62 T, N, ER, systemic therapy
Azim et al. 2012 [9] ≤40 (339) >40 (2,562) Relapse-free survival 1.34 1.10-1.63 T, N, grade, BC molecular
subtype, systemic therapy
aIn multivariate models. BC, breast cancer; CI, confidence interval; ER, estrogen receptor; n, number; N, nodal involvement; PgR, progesterone receptor; T, tumor size.
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younger patients. Similar results were also reported by the
Korean Breast Cancer Society registry, which included
9,885 premenopausal breast cancer patients aged ≤50 years
at diagnosis [8].
In comparing groups of very young women, however,
Collins and colleagues [12] did not find significant differ-
ences in histological features or the expression of ER,
PgR and HER2 between patients aged ≤30 (n =47), 31 to
35 (n =111) and 36 to 40 (n =241) years at breast cancer
diagnosis in a prospective study, except for a trend of
higher tumor necrosis in the youngest group (32% versus
14% and 21%, P=0.06). A retrospective analysis of 500
patients who were aged <35 years at the time of diagnosis
reported the same findings, albeit a modest higher pre-
valence of ER-negative (31% versus 23%), and highly prolif-
erative tumors (ki67> 30%; 59% versus 49%) among
patients aged <30 and 30 to 34 years, respectively [19]. Col-
lectively, these findings suggest that the younger the
p a t i e n t ,t h em o r ea g g r e s s i v et h et u m o rf e a t u r e sw i t h i n
the premenopausal population. Yet, it appears that dif-
ferences are more subtle in women below 35 or 40 years.
Molecular profiling of breast cancer in young
women
Gene expression differences
In 2008, Anders and colleagues [20] published one of
the first attempts to describe the biology of breast
cancer in young women using gene expression profiling.
In this analysis, which included 200 patients in the
young group (≤45 years) and 211 patients in the control
group (≥65 years), a higher probability of phosphatidyli-
nositide 3-kinase (PI3K; P =0.006) and Myc (P =0.03)
pathway deregulation was observed in tumors arising in
younger patients. However, this analysis was not adjusted
for potential differences in breast cancer molecular sub-
types as well as other known prognostic factors. Subse-
quently, a similar analysis was performed by the same
group with appropriate adjustment for molecular subtypes
among other features [17], using two publicly available
datasets; the first including 48 patients aged ≤45 years and
144 patients ≥65 years, and the second including 92
patients ≤45 years and 108 patients ≥65 years. As ex-
pected, younger patients in their datasets had more
basal-like tumors but, after adjustment for subtype
differences, no distinct molecular aberrations were found
that were related to age.
More recently, Azim and colleagues [9] conducted a
pooled gene expression analysis on two datasets includ-
ing 1,188 and 2,334 patients. The aim was to evaluate
the association between patients’ age and nearly 50 genes
that were identified based on literature search to be
related to early-onset breast cancer. The analysis was ad-
justed for differences in breast cancer molecular subtype,
histological grade, tumor size, and nodal status. Results
on the first dataset (n =1,188, ≤40 years = 191) showed
Azim et al, 2012 [9]
Subtypes defined by
3 gene classifier 
Anders et al, 2011 [17]
Subtypes defined by
PAM50
HER2 Luminal-A Luminal-B Basal
Breast cancer subtypes according to age determined by gene expression profiling  
Figure 1 Breast cancer subtypes. Subtypes determined by gene expression profiling.
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tients have higher expression of RANK-ligand (P< 0.0001),
c-kit (P <0.001), in addition to mammary stem cell
(P < 0.0001) and luminal progenitors and BRCA1 muta-
tion signatures (P=0.007). In addition, there was more
disruption of the mitogen-activated protein kinase
and PI3K pathways (P < 0.0001) and lower expression
of BRCA1 (P=0.003) and several apoptosis-related genes,
particularly FAS (P=0.03). The very same findings were
reproduced in an independent dataset that included 2,334
patients, of whom 260 were aged ≤40 years. At a glance
these results appear in direct conflict with those of Anders
and colleagues [17]. However, the Anders analysis in-
cluded four times fewer patients and utilized an unbiased
approach in searching for genes associated with age, which
requires a relatively high number of patients, especially
with adjustment for several confounders and multiple
comparisons.
The results by Azim and colleagues suggest interesting
insights into the biology of early onset breast cancer. The
high BRCA1 mutation signature expression is consistent
with the known relatively high prevalence of BRCA1 muta-
tions in younger patients [21,22]. Patients with BRCA1 mu-
tations are commonly diagnosed with basal-like tumors
[23]; earlier work suggested that luminal progenitors appear
to be the cell of origin of these tumors and are regulated by
c-kit [24]. The high expression of the BRCA1 mutation sig-
nature, luminal progenitors and c-kit in younger patients
all may suggest why young women tend to develop basal-
like tumors at higher frequencies. The high expression
of RANKL (Receptor activator of nuclear factor kappa-B
ligand) is also intriguing given RANKL is known to
stimulate osteoclastogenesis and targeting RANKL has
been shown to reduce risk of osteoporosis and related
skeletal events secondary to bone metastases [25].
RANKL has also emerged as a PgR-regulated gene that
is involved in the expansion of mammary stem cells, in-
creasing their proliferation and protecting them from
undergoing apoptosis [25]. In young women, the normal
breast is enriched with an immature mammary cell
population (that is, stem cells and progenitors), which
increases during pregnancy and breastfeeding, an effect
Cancello et al, 2010 [7]
Luminal-A: ER+ or PgR+ / HER2-/  Ki < 14%
Luminal-B: ER+ or PgR+ / HER2- / Ki ≥ 14%
Luminal-B/HER2+: ER+ or PgR± / HER2+
HER2+: ER+ / PgR- / HER2-
Triple negative: ER-/  PgR- / HER2-
Morrison et al, 2012 [18]
Luminal-A: ER+ / PgR± / HER2-/ Ki ≤ 14%
Luminal-B: ER+ / PgR± / HER2-/ Ki > 14%
Luminal-B/HER2+: ER+ / PgR± / HER2+
HER2+: ER+ / PgR- / HER2-
Triple negative: ER-/  PgR- / HER2-
Collins et al, 2012 [12]
Luminal-A: ER+  and/or PgR+ / HER2-/  Grade I or II
Luminal-B: ER+  and/or PgR+ / HER2+ or ER+ / Grade III
HER2+: ER+ / PgR- / HER2-
Triple negative: ER-/  PgR- / HER2-
Breast cancer subtypes according to age determined by immunohistochemistry (IHC)
HER2 Luminal-A Luminal-B Triple Negative Luminal-HER2
33 %
21%
25%
11% 
≤ 40
(n=399)
Figure 2 Breast cancer subtypes. Subtypes determined by immunohistochemistry. ER, estrogen receptor; PgR, progesterone receptor.
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[26]. In preclinical breast cancer models, RANKL in-
hibition arrested progestin-induced cancer and reduced
the mammary stem cell component [27]. Thus, RANKL
appears to be a potentially relevant breast cancer target
beyond its established role in managing bone metastases.
Prognostic genomic signatures in young breast
cancer patients
Currently several genomic tests are available to improve
prognostication and aid decision making in the adjuvant
setting [16]. This includes Oncotype Dx®, Mammaprint®,
Endopredict, PAM50, Breast Cancer Index and many
others [28]. They add prognostic information to classic
prognostic variables in patients with ER-positive tumors
and appear to distinguish reliably between patients at
low and high risk of recurrence [28]. They are increas-
ingly integrated in standard clinical practice, yet there
have been concerns about whether they carry the same
prognostic value in young women given these signatures
were mainly developed using populations of postmeno-
pausal women.
The initial work by the Dutch group on MammaPrint®
including 295 patients, only 63 (21%) of whom were
younger than 40 years, revealed 52/63 young patients
(82%) were classified as high risk [29]. The same was ob-
served in earlier studies with Oncotype Dx®, where only
59 out of 668 patients were aged less than 40 years, yet
the majority had a high risk score (33/59 young patients;
56%) [30]. This was somewhat higher than the propor-
tions in the high risk group in patients aged 40 to 50
(29%), 50 to 60 (25%) and >60 years (21%). The other
signatures were also largely developed using populations
of older patients and hence it is hard to extrapolate from
these studies the value of genomic signatures in the
young population.
A pooled gene expression analysis recently addressed
the prognostic value of three signatures according to
age: GENE70 (the microarray version of MammaPrint®),
the genomic grade index and GENE76 [9]. In an ana-
lysis including 755 patients with ER-positive disease, of
whom 87 were aged ≤40 years, each of the genomic
signatures was significantly associated with disease-
free survival and added significant prognostic infor-
mation to the clinical risk classifier, Adjuvant Online.
The prognostic value was the same across all age groups,
suggesting that genomic signatures can add prognostic in-
formation in younger as well as older women with breast
cancer.
Pattern of mutations in young breast cancer patients
Several recent studies have reported on the landscape of
somatic mutations in breast cancer using next gener-
ation sequencing [31-33]. Point mutations have been
observed in TP53 and PIK3CA genes, accounting for
nearly 25% of cases. However, very little is known regard-
ing the pattern of somatic mutations in younger women.
Stephens and colleagues [33] conducted whole genome
sequencing of 100 breast tumors but found no correlation
between total number of somatic base substitution and
age at diagnosis in both ER-positive (P=0. 33 ) a nd ER -
negative (P=0.14) tumors.
Recently, the pattern of hot spot somatic mutations
using Sequenom was evaluated in 167 young breast
cancer patients (mean age of 36 years), of whom 54 were
diagnosed during pregnancy [34]. A total of 84 mutations
in 19 genes were evaluated, including 29 different muta-
tions of PIK3CA (94% of known mutations), and 7 and 6
mutations for ERBB2 and TP53, respectively. No differ-
ences were observed between the pregnant and non-
pregnant groups. While this study lacked a control group,
the prevalence of mutations particularly in PIK3CA ap-
peared to be in line with their known prevalence in
older women: approximately 23%. Only 5% of patients
had a TP53 mutation, although it should be noted that
only 12% of known P53 mutations were explored in
this study. No ERBB2 mutations were observed at all.
Regarding germline mutations, BRCA1/2 mutations are
the most common, accounting for up to 40% of familial
breast cancer [35]. In a large analysis including 3,345 pa-
tients who were aged ≤50 years at the time of breast can-
cer diagnosis, 7% of patients had a BRCA1 mutation [21].
However, BRCA1 carriers were significantly younger
(mean age 41.9 versus 44.1, P<0.001), and had more ER-
negative (84.1% versus 38.1%, P<0.001) and HER2-
negative (93% versus 79%, P<0.001) tumors.
Data on other familial breast cancer syndromes in
young women are very scarce. CHEK2*1100delC is an-
other germline mutation that has been described to occur
more commonly in younger patients. A recent study from
Denmark evaluating 25,571 patients found that 1.8% were
CHEK2*1100delC heterozygous [36]. These patients were
younger and were more likely to be premenopausal and
have ER-positive disease (all P<0. 00 1) .
The fact that women with familial breast cancer syn-
dromes appear to develop the disease more frequently at
an earlier age adds further complexity to the biological
make-up of breast cancer in young women. Further
research to elucidate the triggers for the development of
disease in this high risk young population in particular is
clearly warranted.
Impact of pregnancy/breastfeeding on breast
cancer biology
Reproductive behavior and biology of subsequent
breast cancer
Decades ago it was shown that pregnancy increases
breast cancer risk in the short term but has a long-term
Azim and Partridge Breast Cancer Research 2014, 16:427 Page 5 of 9
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have evaluated the relationship between different repro-
ductive behaviors and not only the risk but also the
phenotype of subsequent breast cancer [38-42] (Table 2).
R e c e n ts t u d i e ss u g g e s tap r o t e c t i v ee f f e c to fp a r i t yo n
the development of ER-positive tumors at the expense
of a relatively higher proportion of patients diagnosed
with triple-negative disease particularly in the absence
of breastfeeding. On the other hand, breastfeeding appears
to be protective against triple-negative breast cancer
[38,40,42]. This is also true for BRCA1 carriers, in whom
breastfeeding for 1 or 2 years was shown to be associated
with a 32% and 49% reduction in breast cancer risk,
respectively [43]. Breastfeeding was protective for both
early- and late-onset cancers in this high risk population.
The biological explanation of the effect of pregnancy
and breastfeeding on breast cancer risk is poorly under-
stood. Russo and colleagues [44] compared gene ex-
pression profiles of microdissected epithelial cells from
normal breast tissue of 41 parous and 8 nulliparous
post-menopausal breast cancer patients with those of
18 parous and 7 nulliparous post-menopausal women
without breast cancer. They found that parous non-
cancer patients had unique gene expression patterns
including differential expression of apoptosis-related
genes and others related to cell cycle and cell signaling.
This suggested that pregnancy may induce a signature
that protects from developing breast cancer. However, this
study was based on few study subjects, and lacked long-
term follow-up to confirm that the parous non-cancer
group did not develop subsequent breast cancer. Asztalos
and colleagues [45] studied gene expression patterns in
human breast after pregnancy to try to elucidate the bidir-
ectional effect of pregnancy on cancer risk. They grouped
52 young women (median age 29 years) as nulliparous, re-
cently pregnant (that is, 0 to 2 years since last pregnancy)
and distantly pregnant (that is, 5 to 10 years since last
pregnancy) and evaluated a panel of 64 genes related to
immune, angiogenesis, extracellular remodeling and hor-
mone signaling. The parous groups had lower expression
of ERα, PgR, and HER2 but higher expression of ERβ and
inflammation-associated genes. No considerable differ-
ences were observed between the recently and distantly
pregnant groups. A more recent preclinical study was
able to show that parity downregulates Wnt/Notch
signaling and suppresses progenitor cells, suggesting that
this could be a potential mechanism explaining the
long-term protective effect of pregnancy [46].
Pregnancy-associated breast cancer
Several studies and a recent meta-analysis have shown
that patients diagnosed with breast cancer during or
shortly after pregnancy have poor prognosis, particu-
larly those diagnosed shortly after pregnancy [47].
Clearly, delays in diagnosis in this unique population
has some effect, although it is also plausible that the
hormonal milieu and the massive increase of female
sex hormones during pregnancy can modulate the breast
microenvironment, and consequently stimulate aggressive
tumor growth. An alternative hypothesis is that the pro-
cesses of breast involution that occurs following delivery,
similar to wound healing where angiogenesis, inflammation
and extracellular matrix alterations are activated, re-
sults in more aggressive breast cancer biology [48].
Schedin and colleagues [49,50] have developed a pre-
clinical model investigating the impact of post-partum
mammary involution on breast cancer initiation and
progression. In this model, tumors developing in an invo-
luting breast were larger, greater in number and had a
higher proliferation index compared to those developing
in a nulliparous breast. They reported that this pheno-
menon was related to high deposition of collagen and
expression of Cox-2 in both the tumor and the involuting
breast. Furthermore, inhibition of Cox-2 by a Cox-2 in-
hibitor resulted in reductions in the size of the tumors
arising in the involuting breast. This study provided a
proof-of-concept that pregnancy alters the breast micro-
environment, which could subsequently impact tumor
development and tumor biology.
In patients diagnosed during pregnancy, several ana-
lyses of clinical data have not revealed different expres-
sion of key biomarkers like ER and HER2 compared
Table 2 Recent large studies investigating the impact of pregnancy and breastfeeding on the risk of developing breast
cancer according to biology
Population Number Impact of parity on breast cancer
risk according to subtype
Impact of breastfeeding on breast
cancer risk according to subtype
Shinde et al. 2010 [38] MD Anderson 2,473 Increase TNBC risk Reduce TNBC risk
Palmer et al. 2011 [39] African American 457 Reduce ER+BC risk Reduce TNBC risk
Redondo et al. 2012 [40] Spanish 501 Reduce TNBC risk
Chung et al. 2013 [41] Korean 6,952 Reduce ER+BC risk
Li et al. 2013 [42] American 1,962 (<45 years) Reduce ER+BC risk Reduce TNBC risk
BC, breast cancer; ER+, estrogen receptor-positive; TNBC, triple-negative breast cancer.
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[51-53]. A recent gene set enrichment analysis that
included 54 pregnant and 113 age- and stage-matched
non-pregnant breast cancer patients revealed that tumors
diagnosed during pregnancy were associated with acti-
vated signaling pathways like the serotonin receptor path-
way and G-protein-coupled receptor pathway [34]. There
was also high expression of relevant cancer targets related
to PD1/PDL1, SRC, insulin growth factor and Wnt/β-ca-
tenin. The expression of these genes in normal breast
increased steadily over the course of pregnancy in a mouse
model, underscoring the potential role of the breast micro-
environment during pregnancy on the tumor phenotype.
While it is difficult to validate these experiments clinically
given the rarity of the disease and complexities of enrolling
pregnant women into clinical trials, these collective find-
ings underline that changes that occur during pregnancy
and in the post-partum period likely impact the biology of
breast cancer development in young women. These
changes are most likely induced by the hormonal and in-
flammatory changes in these periods, and the resulting
perturbation of the breast microenvironment. However,
current data do not confirm that such effects play a key
role in driving carcinogenesis and tumor biology.
Future directions
There is clear evidence that breast cancer arising at a
young age is more aggressive and has potentially unique
biological features and that events occurring during the
childbearing period, including pregnancy and breastfeeding,
impact on not only breast cancer risk but also breast cancer
phenotype and biology. Nevertheless, to date, manage-
ment strategies are often the same irrespective of age and
hence there is a need to adapt a biology-driven approach to
refine treatment for younger breast cancer patients [54].
These patients have a relatively high risk of relapse and
hence it would be vital to integrate novel genomic tools to
refine the treatment-decision process. Genomic tests could
guide not only those patients who derive little benefit from
adjuvant chemotherapy but also those who might be
more suitable for extended adjuvant therapy, a strat-
egy that has proven effective in recent studies [55,56].
Three genomic signatures, PAM50, Endopredict and Breast
Cancer Index, were shown to reliably determine risk of re-
currence beyond 5 years [57-59]. Considering that nearly
40 to 50% of young ER-positive patients relapse after 5 years
[11], they could serve as a tool to identify those that would
derive higher benefit from extended adjuvant therapy. This
approach needs to be validated in clinical trials.
Based on the results obtained from the large gene ex-
pression analysis showing high expression of RANKL in
younger patients, a preoperative window trial is currently
ongoing to evaluate the impact of denosumab, a RANKL
inhibitor, on the biology of breast cancer in young women
(D-BEYOND; NCT01864798). This study could poten-
tially define a role for denosumab in future management
of young patients.
Another ongoing study in patients with pregnancy-
associated breast cancer is investigating the role of Cox-2
inhibition (NCT01881048). Patients in the post-partum
period will receive one week of celecoxib to evaluate its
effect on the proliferation marker ki67 prior to surgical
intervention.
Poly ADP ribose polymerase inhibitors are emerging as
very promising drugs in managing patients with BRCA1
or BRCA2 mutations [60]. A study in the adjuvant setting
is currently evaluating the value of 1 year of adjuvant ola-
parib in BRCA1 mutated patients (NCT02032823) and a
relatively large number of young patients will likely enroll.
In light of the emerging evidence that young women
with luminal-B tumors have particularly disparate out-
comes, and in consideration of the high deregulation of
the PI3K pathway in tumors arising in young patients
[9,20] and its vital role in endocrine resistance [61],
targeting the PI3K pathway is an approach that is worth
investigating further in young breast cancer patients. Tar-
geting premature mammary cell subpopulations that ap-
pear to be abundant in younger patients is also worth
exploring with agents such as Notch inhibitors, a novel
class targeting stem cells-like features [62].
Finally, better characterization of somatic mutations
occurring in tumors arising in young women using next
generation sequencing could further identify key driver
mutations that can be targeted in this challenging dis-
ease. These strategies and others underscore that a lot of
work is still required to elucidate the biology and con-
sequently improve the outcomes of young women with
breast cancer.
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